Advertisement
Clinical Therapeutics
Advanced searchSave search
Editorial| Volume 22, ISSUE 1, P114-115, January 2000

Editorial Comment

DOI:https://doi.org/10.1016/S0149-2918(00)87982-5
Editorial Comment
Previous ArticleOngoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: Year-three results
Next ArticleEconomic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0149-2918(00)87982-5

      Copyright

      © 2000 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX